Following the excitement last month of Human Genome Sciences Inc.'s successful Phase III trial of its lupus drug - which sent the firm's shares on a 277 percent rocket ride on July 20 - Immunomedics Inc. and UCB SA Thursday said their drug epratuzumab had a 24.9 percent treatment advantage over placebo in patients with systemic lupus erythematosus (SLE) in a Phase IIb dosing study. (BioWorld Today) Read More
